BioRestorative Therapies, Inc.

Symbol: BRTX

NASDAQ

1.43

USD

Market price today

  • -0.5855

    P/E Ratio

  • -0.0214

    PEG Ratio

  • 9.68M

    MRK Cap

  • 0.00%

    DIV Yield

BioRestorative Therapies, Inc. (BRTX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-0.53%

Operating Profit Margin

-104.39%

Net Profit Margin

-78.85%

Return on Assets

-0.91%

Return on Equity

-0.91%

Return on Capital Employed

-1.32%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Lance Alstodt
Full-time employees:11
City:Melville
Address:40 Marcus Drive
IPO:2012-12-05
CIK:0001505497

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

General Outlook

When we look at how much money they make before expenses, they keep -0.535% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -104.395%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -78.852%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.912% return, is a testament to BioRestorative Therapies, Inc.'s adeptness in optimizing resource deployment. BioRestorative Therapies, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.915%. Furthermore, the proficiency of BioRestorative Therapies, Inc. in capital utilization is underscored by a remarkable -1.318% return on capital employed.

Stock Prices

BioRestorative Therapies, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.55, while its low point bottomed out at $1.23. This variance in figures offers investors a lucid insight into the roller-coaster ride that is BioRestorative Therapies, Inc.'s stock market.

Liquidity Ratios

Analyzing BRTX liquidity ratios reveals its financial health of the firm. The current ratio of 1071.15% gauges short-term asset coverage for liabilities. The quick ratio (1042.45%) assesses immediate liquidity, while the cash ratio (83.17%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1071.15%
Quick Ratio1042.45%
Cash Ratio83.17%

Profitability Ratios

BRTX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -7937.81% underscores its earnings before tax deductions. The effective tax rate stands at 1.86%, revealing its tax efficiency. The net income per EBT, 99.34%, and the EBT per EBIT, 76.04%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -10439.49%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-7937.81%
Effective Tax Rate1.86%
Net Income per EBT99.34%
EBT per EBIT76.04%
EBIT per Revenue-10439.49%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 10.71, it details the span from stock purchase to revenue. The 10 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 755.44% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding1042
Operating Cycle48.32
Days of Payables Outstanding309
Cash Conversion Cycle-261
Receivables Turnover7.55
Payables Turnover1.18
Inventory Turnover223757.00
Fixed Asset Turnover0.29
Asset Turnover0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.37, and free cash flow per share, -1.40, depict cash generation on a per-share basis. The cash per share value, 2.35, showcases liquidity position. Lastly, the operating cash flow sales ratio, -44.10, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.37
Free Cash Flow per Share-1.40
Cash per Share2.35
Operating Cash Flow Sales Ratio-44.10
Free Cash Flow to Operating Cash Flow Ratio1.03
Cash Flow Coverage Ratio-39.62
Short Term Coverage Ratio-39.62
Capital Expenditure Coverage Ratio-37.59
Dividend Paid and Capex Coverage Ratio-37.59

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.29%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. An interest coverage of 86.45 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio1.29%
Debt Equity Ratio0.01
Total Debt to Capitalization1.39%
Interest Coverage86.45
Cash Flow to Debt Ratio-39.62
Company Equity Multiplier1.09

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.03, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.42, reflects the portion of profit attributed to each share. The book value per share, 2.74, represents the net asset value distributed per share, while the tangible book value per share, 2.57, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.03
Net Income Per Share-3.42
Book Value Per Share2.74
Tangible Book Value Per Share2.57
Shareholders Equity Per Share2.74
Interest Debt Per Share0.04
Capex Per Share-0.04

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 21.70%, indicates top-line expansion, while the gross profit growth, 87.61%, reveals profitability trends. EBIT growth, 19.78%, and operating income growth, 19.78%, offer insights into operational profitability progression. The net income growth, 19.98%, showcases bottom-line expansion, and the EPS growth, 31.33%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth21.70%
Gross Profit Growth87.61%
EBIT Growth19.78%
Operating Income Growth19.78%
Net Income Growth19.98%
EPS Growth31.33%
EPS Diluted Growth31.33%
Weighted Average Shares Growth16.60%
Weighted Average Shares Diluted Growth16.60%
Operating Cash Flow Growth-9.53%
Free Cash Flow Growth-4.60%
10-Year Revenue Growth per Share-99.51%
5-Year Revenue Growth per Share-99.91%
3-Year Revenue Growth per Share-82.28%
10-Year Operating CF Growth per Share99.99%
5-Year Operating CF Growth per Share99.91%
3-Year Operating CF Growth per Share69.37%
10-Year Net Income Growth per Share99.99%
5-Year Net Income Growth per Share99.92%
3-Year Net Income Growth per Share88.99%
10-Year Shareholders Equity Growth per Share100.01%
5-Year Shareholders Equity Growth per Share100.09%
3-Year Shareholders Equity Growth per Share181.15%
Receivables Growth20.63%
Asset Growth-23.26%
Book Value per Share Growth-37.44%
Debt Growth-46.19%
R&D Expense Growth14.84%
SGA Expenses Growth-28.33%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 6,617,863.78, captures the company's total value, considering both debt and equity. Income quality, 0.45, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 76.57, gauges operational efficiency, while the research and development to revenue, 2767.21%, highlights investment in innovation. The ratio of intangibles to total assets, 5.66%, indicates the value of non-physical assets, and capex to operating cash flow, 2.66%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value6,617,863.78
Income Quality0.45
Sales General and Administrative to Revenue76.57
Research and Development to Revenue2767.21%
Intangibles to Total Assets5.66%
Capex to Operating Cash Flow2.66%
Capex to Revenue-117.31%
Capex to Depreciation-103.20%
Stock-Based Compensation to Revenue5338.11%
Graham Number14.51
Return on Tangible Assets-121.16%
Graham Net Net2.37
Working Capital10,327,134
Tangible Asset Value10,834,636
Net Current Asset Value10,327,134
Average Receivables17,650
Average Payables180,145.5
Average Inventory1
Days Sales Outstanding48
Days Payables Outstanding417
ROIC-129.97%
ROE-1.25%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.58, and the price to book ratio, 0.58, reflect the market's valuation relative to the company's book value. The price to sales ratio, 66.40, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.47, and price to operating cash flows, -1.05, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.58
Price to Book Ratio0.58
Price to Sales Ratio66.40
Price Cash Flow Ratio-1.05
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-0.69
Price Fair Value0.58
Price to Operating Cash Flow Ratio-1.05
Price to Free Cash Flows Ratio-1.47
Price to Tangible Book Ratio0.64
Enterprise Value to Sales45.39
Enterprise Value Over EBITDA-0.44
EV to Operating Cash Flow-1.03
Earnings Yield-196.40%
Free Cash Flow Yield-89.94%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of BioRestorative Therapies, Inc. (BRTX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.585 in 2024.

What is the ticker symbol of BioRestorative Therapies, Inc. stock?

The ticker symbol of BioRestorative Therapies, Inc. stock is BRTX.

What is company IPO date?

IPO date of BioRestorative Therapies, Inc. is 2012-12-05.

What is company current share price?

Current share price is 1.430 USD.

What is stock market cap today?

The market cap of stock today is 9680986.000.

What is PEG ratio in 2024?

The current -0.021 is -0.021 in 2024.

What is the number of employees in 2024?

In 2024 the company has 11.